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Abstract
The seriousness of ovarian cancer, which is related to the observed link between recurrency and cell cycle control defect,
prompted us to explore the effect of ectopic expression of the cdk inhibitor p21cip1/waf1 on ovarian carcinoma chemosensitivity.
The transfection of p21cip1/waf1 cDNA into SKOV3 and OVCAR3 cells led to reduction of tumor cell growth, enhanced
susceptibility to cisplatin-induced apoptosis, and abolition of recurrency after cisplatin exposure. p21cip1/waf1 gene transfer
allowed a marked reduction of the cisplatin concentration needed to erradicate the tumor cell population. These results suggest
exploring the possible use of p21cip1/waf1 as an adjunctive to conventional chemotherapy. q 2000 Elsevier Science Ireland Ltd.
All rights reserved.
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1. Introduction
Chemoresistance is a major concern in cancer
chemotherapy. Ovarian carcinoma is an example of
cancer in which intrinsic and acquired resistance are
clinically apparent. Aggressive treatment of the
patients with platinum-based combination chemother-
apeutic regimens produces a high primary rate of
complete clinical complete response to the drug.
However a large proportion of patients relapse,
become refractory to the initial drugs used, and even-
tually die of their disease within 5 years. Several
mechanisms of resistance to platinum compounds
have been identi®ed, including decreased intracellular
drug accumulation, enhanced detoxi®cation mechan-
isms, DNA repair, and tolerance toward platinum
adducts [1]. Since most chemotherapeutic agents
exert their cytotoxic effect on tumor cells by inducing
apoptotic cell death [2], defects in the apoptosis
program have also been suggested to be responsible
for chemoresistance in malignant cells [1,3]. Having
established an in vitro cellular model of chemoresis-
tance in human ovarian carcinoma cells by mimicking
a clinical protocol of cisplatin treatment, we found
that the acquisition of chemoresistance was not
directly linked to a defect in apoptosis induction, but
rather to a defect in cell cycle control favoring the
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proliferation of a few recurrent cells that had acquired
a chemoresistant phenotype [4].
The most common genetic alteration in human
cancer, including ovarian cancer, involves the p53
tumor suppressor gene [5,6]. This results in defective
control of cell cycle arrest and cell death following
exposure to DNA-damaging agents [7], and thereby in
genomic instability. p53 encodes a transcriptional
factor for a set of genes involved in the regulation
of cell cycle progression, DNA repair, and apoptosis.
One of the targets for p53-dependent transcriptional
activation is the cyclin-dependent kinase (cdk) inhi-
bitor p21cip1/waf1, a negative regulator of cell cycle
transitions following DNA damage [8±10]. p21 is
also inducible in a p53-independent manner [11,12].
The cell cycle inhibitory effects of p21 may be attrib-
uted to its ability to bind cdks as well as the prolifer-
ating cell nuclear antigen (PCNA) [13,14], resulting
in inhibition of progression from the G1 to the S
phase, of DNA replication, and of progression through
G2 phase [15]. In normal cells, p21, cyclin, cdk, and
PCNA can form a tetrameric complex in which the
binding of more than one p21 molecule is needed to
inhibit the cdk activity.
Gene transfer of p21 inhibits tumor cell growth in
vitro and in vivo, as reported for melanoma cells [16],
breast carcinoma cells [17,18], lung cancer cells [19],
colorectal carcinoma cells [20], and oncogene-trans-
formed ®broblasts [21]. Having uniformly demon-
strated the negative effect of p21 on malignant cell
proliferation, all these data stress the potential of p21
to serve as a tumor suppressor for therapeutic
purposes. However, inhibition of cell growth may
not be suf®cient to eradicate ef®ciently a tumor and
should be associated with enhanced tumor cell death.
The effect of p21 upregulation on apoptosis induction
is controversial. p21 failed to induce apoptosis in
normal and tumor cells of lung and mammary epithe-
lial origin [17], whereas it induced the formation of
giant cells that ultimately succumbed to apoptotic
death in breast carcinoma [18] and colorectal carci-
noma [22]. Other studies have also reported that p21
appears to protect from apoptosis [23±26], and p21-
de®cient cells are more sensitive to killing by irradia-
tion than their p21-expressing counterparts [27].
Based upon data on the growth inhibition ef®ciency
of p21 on a variety of malignant cell types, the aim of
the present work was to determine the potential effect
of p21 on ovarian carcinoma cell growth in vitro,
alone or in combination with cisplatin.
2. Materials and methods
2.1. Cell lines
The human ovarian adenocarcinoma cell lines
SKOV3, OAW42, and OVCAR3 were grown as
monolayers at 378C in a 5% CO2 atmosphere.
SKOV3 was grown in Mac Coy's medium supple-
mented with 10% fetal calf serum (Gibco BRL,
Cergy-Pontoise, France) and 2 mM l-glutamine;
OAW42 in DMEM supplemented with 10% fetal
calf serum, 2 mM l-glutamine, 1 mM sodium pyru-
vate, and 2 mg/ml bovine insulin (Gibco BRL); and
OVCAR3 in RPMI 1640 supplemented with 20%
fetal calf serum, 2 mM l-glutamine, 2.5g/l d-glucose,
1 mM sodium pyruvate, and 10 mg/ml bovine insulin.
The medium was replaced every 2 days. The cell lines
were subcultured weekly, through detachment with
tryspin/EDTA (Gibco BRL), at a plating density of
105 per 25 cm2 ¯ask for SKOV3 and OAW42, and
5 £ 105 cells per ¯ask for OVCAR3.
2.2. Drug treatment
Cisplatin (CDDP, cis-diamino-dichloro-platinum
(II)) was obtained in the form of Cisplatylw from
Roger-Bellon (France). Exponentially growing cells
were exposed to CDDP for 2 h at 378C in serum-
free medium. After exposure to the drug, the cells
were rinsed and incubated in the culture medium.
2.3. Construction of expression vector of p21cip1/waf1
A 560 bp fragment of the p21cip1/waf1 cDNA, which
contained the entire coding region, was obtained by
RT-PCR from total RNA of OAW42 cells. In this cell
line expressing wt p53,the cip1/waf1gene can be
induced by serum deprivation for 6 h. The primers
were determined from the published sequence
(GenBank U03106): the forward primer was
5 0-TATGAATTCATTCGCCGAGGCACCGAGGC-
A-3 0 (including EcoRI site at 5 0), and the reverse
primer 5 0-ATTGCGGCCGCTTCCAGGACTGCAG-
GCTTCC-3 0 (including NotI site at 5 0). One micro-
gram of total RNA, extracted by RNAeasy kit
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(Qiagen, Courtaboeuf, France), was reverse-tran-
scribed with 200 units Superscript II reverse transcrip-
tase (Gibco BRL), in ®rst strand reaction conditions
recommended by the manufacturer. The PCR reaction
contained 3 mM MgCl2, 250 mM dNTP, 1 mM of each
primer and 5 units Taq polymerase (Eurobio, Paris,
France) and was run for 25 cycles of successive heat-
ing at 948C for 30 s, 558C for 30 s and 728C for 2 min
within an Amplitronw II Thermolyne thermal cycler
(Bioblock, Illkirch, France). The unique 560 bp
ampli®ed fragment was cleaved with EcoRI and
NotI, and cloned into the pcDNA3.1 vector (In Vitro-
gen), under the control of the cytomegalovirus (CMV)
promoter. Using the ThermoSequenase sequencing kit
(Amersham, Paris, France) and the 5 0-33P-labelled T7
promoter, the sequence of the p21 cDNA insert was
identical to the p21 published sequence. Moreover,
using an in vitro transcription-translation assay
(Promega, Lyon, France), a unique band of 21 kDa
was detected by Western blot with pcDNA-p21, while
no band was detectable with the empty vector.
2.4. Transient cell transfection
Either DPPES (di-palmitoyl-phosphatidylethanola-
mine-spermine) or L-PEI (linear polyethylenimine
22KDa) were used to transfect the expression vector.
DNA-lipopolyamine complexes or DNA-PEI were
obtained as described in [28] and [29], respectively.
Exponentially growing cells were incubated for 3 h in
the presence of the complexes in serum-free medium
and post-incubated in growth medium without rinsing.
Optimal conditions of transfection, assessed with the
Green Fluorescent-Protein expression vector pEGFP
(Clontech, Palo-Alto, CA), were 1 mg DNA/4 nmol
DPPES/105 cells or 1 mg/1.5 nmol L-PEI/105 cells:
this was a compromise between the highest transfec-
tion ef®ciency without toxicity. Control cells were
transfected either with the empty pcDNA vector or
with the pEGFP vector.
2.5. Tet-Off cell line
In order to establish the relationship between p21
level and cell response, we established an inducible
p21-expression system, using the Tet-Off System
(Clontech Laboratories), in which the p21 gene can
be induced after removal of Doxycycline (Dox).
SKOV3 cells were transfected by the pTet-Off regu-
lator plasmid, using DPPES. Stable pTet-Off transfec-
tants were selected by 200 mg/ml of the neomycin
analog G418 (Calbiochem). G418-resistant clones
with low background and high Dox-dependent induc-
tion were screened after transient transfection of the
reporter plasmid pTRE-d2EGFP. These clones were
referred to as SKOV3-Tet-Off and were grown in Mac
Coy's medium supplemented with 10% fetal calf
serum, 2 mM l-glutamine, and 200 mg/ml G418.
SKOV3-Tet-Off cells were transiently transfected
with the pTRE-p21 plasmid, in which the p21
cDNA fragment was cloned in EcoR1 and XbaI
sites, under the control of the tetracycline response
element (TRE). p21 was repressed by 100 ng/ml Dox.
2.6. Assessment of drug cytotoxicity
The drug cytotoxic effect was assessed by two
means: cell enumeration combined with the Trypan
Blue exclusion assay, which analyses total cell death,
and enumeration of apoptotic cells, revealed by their
typical condensed and fragmented nuclear morphol-
ogy visible after staining with DAPI (diamino-2-
phenyl-indol, Boehringer Mannheim) or by TUNEL
procedure, as described previously [4].
2.7. DNA ¯ow cytometry
Cells were prepared as previously described [4] and
samples were analyzed using an EPICS Pro®l I ¯ow
cytometer (Coulter, Paris, France). EPICS Pro®le
Software (Coulter) was run for data acquisition and
MultiCycleAV (Phoenix Flow System) for DNA
ploidy and delineation of different cell cycle compart-
ments.
2.8. Immunodetection of p21cip1in cultured cells
Cells grown on glass coverslips and ®xed with 3%
paraformaldehyde were processed for p21 immunode-
tection as previously described [4], except that the
anti-human p21 was OP64 (Oncogene Research,
Meudon, France) at a 100-fold dilution. Controls,
consisting of cells incubated in the absence of the
primary antibody, were totally negative.
2.9. Western immunoblotting
For Western blots, the conditions of cell lysis, SDS-
PAGE, transfer onto Immobilon-P membranes (Milli-
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pore), and incubation with the antibodies anti-p53
(DO7, Dako) at a 1/5000 dilution or anti-p21 (Onco-
gene Research, OP64) at a 250-fold dilution have
been previously described [4]. Immunoreactivity
was detected by enhanced chemoluminescence
(Amersham).
3. Results
3.1. Cisplatin effects on growth inhibition and
apoptosis
CDDP exerts its cytotoxic effect by inducing apop-
tosis [2]. In both SKOV3 and OAW42 cell lines, the
number of viable cells decreased as a function of drug
concentration (Fig. 1a). The drug concentrations inhi-
biting cell growth by 50 and 100% after 2 days were 5
and 20 mg/ml, respectively, for OAW42 cells, and 10
and 100 mg/ml CDDP, respectively, for SKOV3 cells.
SKOV3 cells appeared, therefore, to be more resistant
than OA4W2 cells to CDDP. The decrease of viable
cell number was related to the commitment to apop-
tosis of the cells exposed to the drug (Fig. 1b): at
concentrations higher than 5 mg/ml CDDP, the
proportion of apoptotic cells was higher for OAW42
than for SKOV3. Using non-lethal CDDP concentra-
tions, we followed OAW42 and SKOV3 cell growth
for several weeks after a pulse exposure to the drug.
Whereas cisplatin-induced apoptosis progressed in the
cell population over several days, cell proliferation in
both cell lines resumed (Fig. 1c) after a period of time.
Despite the presence of 20% apoptotic cells during the
2 days following exposure to 5 mg/ml CDDP, the
number of SKOV3 viable cells remained constant
and a quite normal growth pattern resumed after less
than a week. At the same drug concentration, OAW42
cell number dramatically decreased during 7 days and
the proliferation slowly resumed thereafter, until
recovery to a normally proliferating cell population
after 6±8 weeks. A similar pattern of recovery was
also observed in SKOV3 cells in only 2 weeks after
exposure to a 4-fold higher concentration of CDDP
(20 mg/ml).
3.2. Effect of p21 expression on cell growth
In the CDDP-sensitive OAW42 cells, CDDP
induced the accumulation of p53, and in parallel,
that of p21cip1 (Fig. 2a). SKOV3 cells are defective
in p53 [30]; p21 was basically undetectable and was
not induced after exposure to CDDP. Both the unde-
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Fig. 1. Cisplatin effect on (a) the percent of viable SKOV3 (open
bars) and OAW42 (gray bars) cells remaining 2 days after a 2 h
pulse exposure to the drug, and (b), in parallel, apoptosis induction
determined by nuclear morphology after DAPI staining. The values
in (a) and (b) represents the mean ^ SEM in a representative experi-
ment out of 4 for SKOV3 and 2 for OAW42. (*, not done). In (c),
cell growth was determined at long term after a 2 h pulse exposure
to CDDP: 5 mg/ml in SKOV3 cells (dots), 20 mg/ml in SKOV3 cells
(squares) and 5 mg/ml in OAW42 (triangles). The results are
expressed as the percent of viable cells compared with the number
of cells at the day of treatment. A typical experiment out of three is
shown.
tectable level of p21 and the high dose of drug neces-
sary to totally kill these cancer cells in vitro prompted
us to assess the effects of ectopic expression of p21 on
SKOV3 cell growth. One day after the transient trans-
fection with a cDNA containing the entire translated
sequence of the human waf1/cip1 gene, the expected
560 bp band was present (Fig. 2b), indicating that the
transfected cDNA has been transcribed. The appear-
ance of a p21 protein in the transiently transfected
SKOV3 cells was shown by Western blot and immu-
nostaining (Fig. 2c,d, left). Accumulation of p21
protein was induced in pTRE-p21-transfected
SKOV3-Tet-Off cells, in an inverse correlation with
the concentration of Dox (Fig. 2c,d, right). Immunos-
taining of p21 revealed that the protein accumulated
in the nucleus at a very heterogeneous level. About
40% of the cells were positive.
The effect of p21 expression on cell growth was
evaluated. Two days after transient transfection, the
growth rate was null; it slowly increased thereafter,
remaining at a level of 50% lower than that of controls
(Fig. 3a). The ef®ciency of growth inhibition declined
after 5 days, due to the transient modality of transfec-
tion leading to the progressive loss of p21 expression
after day 3 (data not shown) and to the partial trans-
fection of the cell population. DNA ¯ow cytometry
depicted in Fig. 3b shows a noticeable reduction of the
number of cells in S phase in p21-transfected cells as
compared with untransfected cells, indicating that p21
expression arrested the cells in G1 and G2. The rela-
tionship between growth inhibition and the p21 level
was demonstrated in SKOV3-Tet-Off cells transfected
with pTRE-p21, in which the growth rate was propor-
tional to the level of p21 repression by Dox. As
before, in the presence of p21 expression (0 or 0.1
ng/ml Dox), cell growth was ef®ciently inhibited
during the 4 days following tranfection. Overexpres-
sion of p21 either after transient transfection or induc-
tion after Dox removal did not affect cell morphology
(data not shown).
3.3. Increased cytotoxic effect of CDDP in p21-
expressing cells
To study if p21 expression would affect the cell
sensitivity to CDDP, we exposed p21-transfected
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Fig. 2. (a) Modi®cation of p53 and p21cip1 expression in OAW42
and SKOV3 cells, 6 h after a pulse exposure to 5 (C5) or 20 mg/ml
(C20) CDDP, revealed by Western blot. (b) Expression of p21cip1
mRNA, revealed by RT-PCR, as described in Section 2.3, of
untransfected SKOV3 cells (lane 1), after transfection with a plas-
mid construct encoding p21cip1 (p21-pcDNA, 2 mg) (lane 3) or a
control plasmid (pcDNA3.1, 2 mg) (lane 5). RT-PCR of b-actin
mRNA was used as positive control in untransfected (lane 2),
p21-pcDNA-transfected (lane 4) and pcDNA3.1-transfected (lane
6) cells. In lane 7, p21 cDNA was ampli®ed without reverse tran-
scriptase reaction, to assess the absence of genomic DNA in the
RNA preparations. The base pair ladder at left was given by the
Euroladder M (Eurobio). (c) Western blot of p21 in SKOV3 cells, 1
day after transfection: untransfected cells (lane 1), cells transfected
with 2 mg pcDNA3.1 (lane 2), and cells transfected with 2 mg p21-
pcDNA (lane 3). Western blot of p21 in SKOV3-Tet-Off cells, 1 day
after transfection with 2mg pTRE-p21 plasmid, in the presence of
Dox at 100 ng/ml (lane 4), 10 ng/ml (lane 5), 0.1 ng/ml (lane 6) or
without Dox (lane 7). (d) Immunocytochemistry revealed by a strep-
tavidin±biotin±peroxidase system of untransfected and p21-
pcDNA-transfected SKOV3 cells (left), and of pTRE-p21-trans-
fected SKOV3-Tet-Off, with 100 ng/ml Dox or without Dox.
Bars: 10 mm
SKOV3 cells to different concentrations of the drug.
Combination of p21 gene transfert and CDDP
decreased the number of surviving cell, compared
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Fig. 3. Effect of p21cip1 on cell growth. In (a), SKOV3 cells were
transfected with 2 mg p21-pcDNA (black diamonds), or with the
irrelevant pEGFP plasmid (open squares) at 70% con¯uency, and
plated the next day at 25 £ 103 cells per ¯ask. The curve in black
dots represent untransfected cells plated in the same conditions. Cell
growth was determined by cell numeration on duplicate ¯asks,
excluding Trypan Blue-positive cells. In (b), DNA ¯ow cytometry,
expressed as forward scatter (FS) in function of propidium iodide
¯uorescence (FL3), was determined on untransfected (left) and p21-
transfected cells (right), at day 3 after transfection. The phases of the
cell cycle are indicated by an arrow. In (c), SKOV3-Tet-Off cells
were transfected with pTRE-p21 at day 0 and incubated in the
presence of decreasing concentration of Dox: 100 ng/ml (black
squares), 10 ng/ml (open squares), 0.1 ng/ml (open dots) or without
Dox (back dots). Cell growth was evaluated as in (a).
Fig. 4. Cytotoxic effect of p21 in combination with CDDP in
SKOV3 cells. Parental SKOV3 cells (open bars) or 2 mg p21-
pcDNA-transfected SKOV3 (black bars) were exposed for 2 h to
increasing concentrations of CDDP, the day following transfection.
Cell viability (a) was determined by Trypan Blue exclusion, 2 days
after drug treatment. Cell mortality (b) represents the proportion of
Trypan Blue-positive cells relative to the total number of cells. The
results are expressed as the mean ^ SEM of duplicates, and corre-
spond to a representative experiment out of four. (c) Morphological
assessment of apoptosis, by DAPI staining (left) or by in situ
TUNEL procedure (right), as described in Section 2.6, the day
following a 2 h pulse exposure to 20 mg/ml CDDP. Apoptotic
cells display a fragmented nucleus, with condensed chromatine,
visible as well after DAPI staining than after TUNEL reaction.
with CDDP alone (Fig. 4a). For example, the number
of residual cells after the association p21-20 mg/ml
CDDP was two times lower than that of cells surviv-
ing 50 mg/ml CDDP without tranfection, indicating
that p21 decreased by at least a factor two the concen-
tration of CDDP necessary to achieve the same reduc-
tion of tumor cells. The p21-CDDP combination
actually enhanced cell death (Fig. 4b). In the absence
of CDDP, p21 gene transfert gave rise to a low propor-
tion (4%) of dead cells; in the presence of CDDP, the
proportion of dead cells was enhanced in p21-trans-
fected cells as compared with parental cells. Apopto-
sis took part of this cell death, since an enhanced
number of cells with characteristic nuclear fragmenta-
tion and positive TUNEL reaction were visible as
soon as one day after CDDP treatment (Fig. 4c).
The enhanced cytotoxic effect of CDDP after p21
transfection was veri®ed in another p21-negative cell
line, OVCAR3. In this cell line also, the reestablish-
ment of p21 expression markedly enhanced the cyto-
toxic effect of CDDP (Fig. 5a). This was con®rmed by
the increased proportion of apoptotic cells and amount
of cell debris after the combination p21/CDDP,
compared with CDDP alone, as depicted in Fig. 5b.
The kinetics of cell viability after a pulse exposure
to CDDP was assessed in pTRE-p21 transfected
SKOV3-Tet-Off in relation to the level of p21 expres-
sion (Fig. 6). Two days after CDDP treatment, cell
growth was stopped at any level of p21 expression.
When p21 was repressed by Dox, cell growth resumed
at a rate inversely correlated to the level of p21. In
particular, pTRE-p21 transfected SKOV3-Tet-Off
incubated with 100 ng/ml Dox behaved like parental
SKOV3 cells in the presence of low concentrations of
the drug (Fig. 1c). When p21 was induced after Dox
omission, the number of residual cells after CDDP
treatment dramatically decreased during several days.
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Fig. 5. Cytotoxic effect of p21 in combination with CDDP in
OVCAR3 cells. OVCAR3 cells were transfected either with
pEGFP (2 mg) or with p21-pcDNA (2 mg), using PEI as described
in Section 2.4. The next day, they were exposed for 2 h to 10 mg/ml
CDDP. In (a) cell mortality was quanti®ed 2 days after drug treat-
ment by the proportion of Trypan Blue-positive cells, relative to the
total number of cells. Western blot of p21 was used to qualitatively
verify p21 expression before and after transfection with p21-
pcDNA. In particular, the decreased p21 level after the combination
p21/CDDP was only due to the decreased number of cells used for
the Western blot. In (b), OVCAR3 cells were stained with DAPI to
detect apoptotic cells two days after drug treatment. Bars: 20 mm
Fig. 6. Kinetics of cell viability of 2 mg pTRE-p21 transfected
SKOV3-Tet-Off cells, after a 2 h exposure to 5 mg/ml CDDP at
day 1, and in the presence of Dox at 100 ng/ml (black squares),
10 ng/ml (open squares), 0.1 ng/ml (open dots) or in the absence of
Dox (back dots). Cell growth was determined as in Fig. 3a.
Cell survival to CDDP was examined after 2
weeks. Parental SKOV3 cells exposed for 2 h to 20
mg/ml CDDP resumed cell growth before 2 weeks, as
described in Fig. 1c, in the form of small colonies,
whereas in p21-transfected cells exposed to the same
dose of drug, no colonies were visible (Fig. 7a).
In pTRE-p21-transfected SKOV3-Tet-Off cells,
recurrent cell growth could be inhibited either by
20 mg/ml CDDP or by the combination of p21 induc-
tion after Dox omission and only 5 mg/ml CDDP
(Fig. 7b).
4. Discussion
The seriousness of ovarian cancer, which is basi-
cally related to the acquisition of chemoresistance
after conventional therapy, combined with extensive
data unanimously indicating the tumor suppressor
effect of p21cip1, prompted us to explore the effect of
ectopic expression of p21 in ovarian carcinoma cells.
In the present report, we show that waf1/cip1gene
transfert enhanced the cytotoxic effect of CDDP and
hindered the proliferation of recurrent ovarian carci-
noma cells.
p21 is a universal and potent cdk inhibitor, in part
under the control of the tumor suppressor gene p53
product [8]. Whereas p53 status is well established in
ovarian cancer, with 50% of the tumors expressing a
mutated form [6], mutations in the waf1/cip1 gene
were not found in ovarian carcinomas [31] or in
tumors in general [32]. Heterogeneous expression of
p21 was described among ovarian cancer cell lines
and in vivo tumor specimens, but was unrelated to
p53 status or to the tumor cell proliferation rate
[33]. p21 mRNA or protein was undetectable in
SKOV3 and in OVCAR3 cells; this could be related
to the defective p53gene in these cell lines [30].
p21 cDNA transient transfection in SKOV3 and
p21 induction in SKOV3-Tet-Off cells led to p21
accumulation in the nucleus of a high proportion of
cells. In consequence, cell growth was reduced in
correlation with the amount of expressed p21: this is
in accordance with a large body of data [8,16±19].
Accumulation of cells in G1 and G2 phase after p21
expression is consistent with its dual inhibitory role of
cdks and PCNA [13±15]. However, p21 alone was
insuf®cient to maintain totally growth inhibition of
SKOV3 cells (Fig. 3) and OVCAR3 cells (data not
shown), in contrast to melanoma cells [16], breast
carcinoma cells [18] or lung cancer cells [19]. In
these tumors, p21 not only restricted cell cycle in
G1/G0 phase, but also altered cell morphology
[18,19] and differentiation [16]. No morphological
changes were observed in any p21-transfected ovarian
carcinoma cell lines as compared with the parental
cell line. The ineffectiveness of p21 to suppress totally
cell growth may be due to an insuf®cient proportion of
transfected cells and/or to a low level of expression.
Indeed, since p21 inhibits a variety of cyclin/Cdk
complexes in a stoechiometric fashion, insuf®cient
expression may allow an active residual pool of
Cdk2, Cdk4, Cdk6, or Cdc2. This could not be
resolved by increasing the amount of DNA or trans-
fection agent, because of undesirable toxicity, which
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Fig. 7. Recurrent cell growth after CDDP treatment. (a) Phase
contrast microphotography of SKOV3 cell culture 14 days after
a pulse exposure to 20 mg/ml CDDP (upper photography), or after
the combination p21-20 mg/mlCDDP (lower photography). Bars:
100 mm. (b) Photography of 2 mg pTRE-p21 transfected SKOV3-
Tet-Off cell plates, colored by Giemsa, 15 days after a pulse expo-
sure to 5 (C5) or 20 (C20) mg/ml CDDP or without CDDP (C).
was also observed with unrelated genes such as that
coding for GFP. Moreover, some cell lines, including
SKOV3, present additional genetic defects conferring
to a growth advantage, such as loss of p16ink4a [34] and
ampli®cation of the oncogene c-erbB2 [35]. Correc-
tion of only one of these defects is likely to be insuf®-
cient to inhibit totally tumor cell growth.
p21-induced cell growth inhibition was accompa-
nied by a slight but reproducible rise of the number of
apoptotic cells, suggesting that p21-transfected cells
became more susceptible to apoptosis. Examining the
effect of p21 on the response to cisplatin, we found
that the cytotoxic effect of the drug was enhanced, as
demonstrated by the increased rate of cell death, the
early induction of apoptosis, and the decreased
concentration of drug needed to achieve the same
cytotoxic effect than in control cells. Whereas p21-
transfection was ef®cient in growth inhibition only for
4±5 days, p21-transfection in combination with
CDDP allowed the erradication of the ovarian tumor
cell population, with a dose of drug much lower than
in parental cells. This suggests that p21 indeed
rendered ovarian tumor cells more sensitive to the
cytotoxic effect of the drug and did not protect them
from cell death. This contrasts with data supporting
the protective role of p21 from apoptosis in other
cancer cells [24±27], which could be linked to its
ability to enhance DNA repair [36,37]. The discre-
pancy in the kinetics of p21-induced growth inhibi-
tion, which lasted 4±5 days, and p21-induced cell
death after CDDP treatment, which lasted at least 2
weeks, raises the possibility of independent p21-
induced pathways responsible for enhanced drug
cytotoxicity and p21-induced cell growth regulation.
p21 gene transfer could have affected some para-
meters determining chemosensitivity, such as drug
uptake and metabolism, DNA repair, and the expres-
sion of apoptosis regulators and effectors. These para-
meters are worth exploring to understand the
mechanism by which this cell cycle inhibitor also
sensitized ovarian tumor cells to a DNA damaging
drug.
Recent studies have suggested that gene transfer
could be used to make conventional chemotherapy
more effective [38,39] or to deliver two co-operating
genes for the induction of apoptosis and tumor growth
inhibition [40]. Reduction of tumor cell growth,
increased sensitivity to apoptotic stimuli, and aboli-
tion of recurrency shown in this report suggest explor-
ing the possible use of p21 as an adjunctive to either
conventional chemotherapy.
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